Article Text

PDF
THU0223 Elevated MTORC1 signature in B cells from sjÖgren's syndrome patients correlates with B cell hyperactivity that is abrogated by MTOR inhibition: a novel therapeutic strategy to halt B cell hyperactivity in PSS?
  1. SL Blokland1,2,
  2. MR Hillen1,2,
  3. CG Kommer-Wichers1,2,
  4. AA Kruize1,
  5. JC Broen1,2,
  6. JA van Roon1,2,
  7. TR Radstake1,2
  1. 1Rheumatology & Clinical Immunology
  2. 2Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands

Abstract

Background A hallmark feature of primary Sjögren's syndrome (pSS) is B cell hyperactivity, including presence of autoantibodies, aberrant presence of B cells and plasma cells in the salivary glands, elevated serum IgG levels and increased risk of lymphoma development. The mTOR pathway is essential for cell growth, survival and proliferation of B cells and mTOR inhibition has been shown to be effective in immune B cell suppression in transplant patients and in treatment of B cell lymphomas. Interestingly, in a pSS mouse model mTOR targeting inhibited lymphocytic infiltration in the lacrimal gland. However, mTOR activation in B cells has not been studied in pSS patients.

Objectives To study the mTOR pathway in B cells of pSS patients as a potential therapeutic target to inhibit B cell hyperactivity.

Methods Expression of mTOR pathway genes (MTOR, RPTOR, RICTOR, DEPTOR, AKT1, IGF1R, IGF1, PTEN) were assessed on an OpenArray platform in purified peripheral blood B cells and monocytes from pSS patients (n=12), non-Sjögren's sicca patients (n=17) and healthy controls (HC, n=9). Correlations with clinical parameters including lymphocytic focus score, ESSDAI and serum IgG levels were assessed. Flow cytometry analysis for B cell subset distribution was performed to assess potential effects of B cell subset distribution on gene expression differences. Culture experiments were performed to study inhibition of the mTORC1 pathway (phosphorylated S6, kinase activity downstream of mTORC1) in association with inhibition of B cell proliferation and IgG production by mTOR inhibition.

Results RPTOR and IGF1R expression were significantly increased in B cells from pSS patients (p=0.019 and p=0.018, respectively) and correlated with serum IgG levels (r=0.429, p=0.020, and r=0.462, p=0.012). Differences in expression of mTOR pathway genes were not found in monocytes. To indicate the mTOR signature a cumulative mTORC1 score was calculated consisting of Z scores (AKT1 + IGF1R + IGF1 + RPTOR + MTOR – PTEN – DEPTOR) which was significantly elevated in pSS (p=0.027), correlating with serum IgG levels (r=0.463, p=0.011). Frequencies of memory and naïve B cells did not differ between pSS patients and HC in this cohort (p=0.415). Activation of B cells in culture resulted in phosphorylation of S6, which indicates increased mTORC1 activity, in accordance with B cell proliferation and IgG production in both HC and pSS patients. Inhibition of mTOR by rapamycin decreased pS6 (n=4, n=2 HC, n=2 pSS, MFI 1400±335 vs 935±306, p=0.060), strongly reduced B cell proliferation (n=6, n=3 HC, n=3 pSS, 80.8±9.9 vs 19.1±15.8%, p<0.001), reduced IgG+ B cells (n=6, n=3 HC, n=3 pSS 39.5±15.5 vs 11.1±5.7%, p=0.001) and decreased IgG production (n=4, n=2 HC, n=2 pSS, 160±180 pg/mL vs 25.3±13.0 pg/mL p=0.060).

Conclusions Presence of an mTORC1 signature in B cells from pSS patients correlating with B cell hyperactivity indicates a role for mTORC1 in B cell activation in this disease. The fact that B cell proliferation and IgG production is effectively inhibited by rapamycin suggests that mTOR inhibition represents a potential therapeutic strategy for pSS.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.